XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
L
L

LaboratoryCorporation

Berita

Reuters - 2 hari yang lalu

NOWDiagnostics And Labcorp Collaborate To Expand Access To The Only Marketing Authorized Over-The-Counter Syphilis Test In The U.S.

BRIEF-NOWDiagnostics And Labcorp Collaborate To Expand Access To The Only FDA-Marketing Authorized Over-The-Counter Syphilis Test In The U.S. Oct 16 (Reuters) - Labcorp Holdings Inc LH.N : NOWDIAGNOSTICS AND LABCORP COLLABORATE TO EXPAND ACCESS TO THE ONLY FDA-MARKETING AUTHORIZED OVER-THE-COUNTER SYPHILIS TEST IN THE U.S. Source text for Eikon: ID
L
Reuters - 1 minggu yang lalu

Labcorp Expands Sexually Transmitted Infection Test Offerings With Rapid Syphilis Test

BRIEF-Labcorp Expands Sexually Transmitted Infection Test Offerings With Rapid Syphilis Test Oct 10 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP EXPANDS SEXUALLY TRANSMITTED INFECTION (STI) TEST OFFERINGS WITH RAPID SYPHILIS TEST LABCORP: PLANS TO MAKE TEST AVAILABLE TO PROVIDERS BY END OF 2024 AND DIRECTLY TO PATIENTS THROUGH LABCORP ONDEMAND I
L
Reuters - 2 minggu yang lalu

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L
Reuters - 2 minggu yang lalu

U.S. Amerant Bancorp, BlackRock, Equinix

U.S. RESEARCH ROUNDUP-Amerant Bancorp, BlackRock, Equinix Oct 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amerant Bancorp, BlackRock and Equinix, on Tuesday. HIGHLIGHTS * Amerant Bancorp Inc AMTB.N : Stephens raises to overweight from equal-weight * BlackRock BLK.N : JP Morgan raises target price to $864 from $774 * Equinix Inc EQIX.O : JP Morgan raises target price to $975 from $950 * Interpublic Group of Comp
A
P
C
L
R
Reuters - 3 minggu yang lalu

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L
Reuters - 3 minggu yang lalu

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L
Reuters - 3 minggu yang lalu

Delay in reimbursement cut to ease pressure on U.S. lab operators, analysts say

BUZZ-Delay in reimbursement cut to ease pressure on U.S. lab operators, analysts say ** Delay in cuts to reimbursement rates for some lab tests under Medicare to aid 2025 rev and earnings of U.S. lab owners such as Labcorp LH.N and Quest Diagnostics DGX.N , analysts say ** LH shares rise 1.1% to $222.73, DGX shares up nearly 1% to $155.51 ** U.S. Congress on Wednesday deferred cuts to reimbursement rates from 2025 to 2026 ** "The delay was in-line with expectations as both LH and DGX have previo
L
Reuters - 4 minggu yang lalu

U.S. Cardinal Health, Factset, Paylocity

U.S. RESEARCH ROUNDUP-Cardinal Health, Factset, Paylocity Sept 23 (Reuters) - .Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cardinal Health, Factset and Paylocity Holding on Monday. HIGHLIGHTS * Cardinal Health Inc CAH.N : Baird raises target price to $140 from $137 * Factset FDS.N : Jefferies raises target price to $486 from $435 * Marinus Pharmaceuticals Inc MRNS.O : Oppenheimer raises to outperform from perform * Paylocity
B
P
V
A
P
C
D
L
L
U
Reuters - 4 minggu yang lalu

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P
Reuters - 4 minggu yang lalu

Cinven To Sell Minority Stake In SYNLAB To Labcorp

BRIEF-Cinven To Sell Minority Stake In SYNLAB To Labcorp Sept 17 (Reuters) - Cinven: CINVEN: TO SELL MINORITY STAKE IN SYNLAB TO LABCORP CINVEN: PURCHASE PRICE FOR INDIRECT MINORITY STAKE OF 15% WAS ABOUT EUR 140 MILLION Further company coverage: LH.N
L
Reuters - 1 bulan yang lalu

Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health

BRIEF-Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health Sept 16 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP COMPLETES ACQUISITION OF SELECT ASSETS OF BIOREFERENCE HEALTH'S DIAGNOSTICS BUSINESS FROM OPKO HEALTH Source text for Eikon: ID:nPnbrzkBja Further company coverage: LH.N
O
L
Reuters - 1 bulan yang lalu

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L
Reuters - 1 bulan yang lalu

Origin of human bird flu case in Missouri still unknown, U.S. CDC says

UPDATE 1-Origin of human bird flu case in Missouri still unknown, U.S. CDC says Adds context in paragraphs 7-12, bylines By Leah Douglas and Julie Steenhuysen WASHINGTON, Sept 12 (Reuters) - Epidemiologists have not yet identified exactly how a person in Missouri contracted bird flu last week, said the U.S. Centers for Disease Control and Prevention on Thursday.
L
Reuters - 1 bulan yang lalu

Origin of human bird flu case in Missouri still unknown, U.S. CDC says

RPT-Origin of human bird flu case in Missouri still unknown, U.S. CDC says Repeats URGENT to attach to snaps WASHINGTON, Sept 12 (Reuters) - Epidemiologists have not yet identified exactly how a person in Missouri contracted bird flu last week, said the U.S. Centers for Disease Control and Prevention on Thursday. The human case was the 14th diagnosed in the U.S.
L
Reuters - 1 bulan yang lalu

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L
Reuters - 2 bulan yang lalu

WHO invites makers of mpox tests for emergency review in push for rapid access

UPDATE 2-WHO invites makers of mpox tests for emergency review in push for rapid access Adds details and background throughout Aug 29 (Reuters) - The World Health Organization on Thursday s ought to speed up the access to diagnostic tests for mpox by asking manufacturers to submit their products for an emergency review. The agency has been in discussions with manufacturers about the need for effective diagnostics, particularly in low-income g roups .
L
Reuters - 2 bulan yang lalu

Diagnostics firm Labcorp weighs ramping up mpox testing capacity

UPDATE 2-Diagnostics firm Labcorp weighs ramping up mpox testing capacity Adds details on other tests from paragraph 6 By Sneha S K Aug 26 (Reuters) - Diagnostics firm Labcorp LH.N said it is working with U.S. health regulators to determine if it needed to ramp up its mpox testing capacity, as countries outside Africa detect a new type of the virus for the first time.
A
L
Reuters - 2 bulan yang lalu

Labcorp Says It Has Capacity To Process About 25,000 Mpox Tests Per Month

BRIEF-Labcorp Says It Has Capacity To Process About 25,000 Mpox Tests Per Month Aug 26 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP SAYS IT IS WORKING CLOSELY WITH US CDC AND PUBLIC HEALTH AGENCIES TO MONITOR MPOX OUTBREAK AND WEIGH NEED FOR INCREASED SUPPLIES OR TESTING LABCORP SAYS CURRENTLY PROCESSING ABOUT 500 MPOX TESTS A MONTH, BUT HAVE CA
L
Reuters - 2 bulan yang lalu

Labcorp Says, Co, Units, Entered Into A Three-Year $300 Mln Accounts Receivable Securitization Facility

BRIEF-Labcorp Says, Co, Units, Entered Into A Three-Year $300 Mln Accounts Receivable Securitization Facility Aug 23 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP - CO, UNITS, ENTERED INTO A THREE-YEAR $300 MILLION ACCOUNTS RECEIVABLE SECURITIZATION FACILITY LABCORP - SECURITIZATION FACILITY CONTAINS ACCORDION TO INCREASE FACILITY LIMIT UP TO $70
L
Reuters - 2 bulan yang lalu

PreciseDx Secures $20.7 Million Series B to Advance Powered Cancer Risk Assessments

BRIEF-PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments Aug 21 (Reuters) - Quest Diagnostics Inc DGX.N : PRECISEDX: RAISED $20.7 MILLION IN SERIES B FUNDING, BRINGING TOTAL FUNDING TO DATE TO $31.5 MILLION PRECISEDX: ADDITIONAL PARTICIPANTS IN ROUND INCLUDE LABCORP, QUEST DIAGNOSTICS, GENHENN CAPITAL VENTURE Sou
L

Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.